US health secretary Robert F. Kennedy Jr. is advancing a proposal to deregulate peptides — short chains of amino acids that function as signaling molecules in the body and are increasingly used in wellness, anti-aging, and performance contexts. The initiative aims to simplify the process by which consumers can purchase peptide-based products, removing layers of regulatory gatekeeping that currently govern their sale and distribution. But the proposal has drawn pointed criticism from those who argue that easier access, absent rigorous evidence of safety and efficacy, may expose consumers to poorly understood risks.
Peptides have gained significant traction in recent years across both the beauty and wellness industries. Compounds such as BPC-157, used for its purported tissue-repair properties, and various growth-hormone-releasing peptides have moved from niche bodybuilding forums into mainstream discourse — amplified by high-profile podcast appearances and social media endorsements. The regulatory framework around these substances has long occupied a gray zone: some peptides are classified as drugs requiring a prescription, others are sold as research chemicals not intended for human consumption, and still others appear in over-the-counter skincare formulations with little oversight. Kennedy's push to deregulate would, in effect, lower the barrier across much of this landscape.
Access versus evidence
The core tension in the debate is not new. Deregulation advocates frame the current system as paternalistic — an obstacle that prevents individuals from making informed choices about their own health. In this view, peptides are relatively simple biological compounds that should not require the same approval pathway as complex pharmaceuticals. The argument carries political resonance in an environment where skepticism toward institutional gatekeeping, whether from the FDA or other agencies, has become a mobilizing force.
Critics, however, point to a fundamental gap: for many peptides circulating in the consumer market, there is limited clinical data supporting the claims made on their behalf. Unlike drugs that have passed through phase-three trials, most commercially available peptides rely on preclinical research — often animal studies or in-vitro experiments — that has not been replicated in controlled human settings. Deregulation without a parallel investment in evidence generation risks creating a market where consumers bear the burden of uncertainty. The beauty and wellness sectors are particularly vulnerable to this dynamic, given the volume of products marketed with language that implies clinical backing without delivering it.
A precedent with broader implications
The peptide debate also carries significance beyond the specific molecules in question. How regulators handle this category could set a template for the treatment of other bioactive compounds — from nootropics to novel anti-aging interventions — that sit at the boundary between supplement and drug. The dietary supplement industry, governed under the 1994 Dietary Supplement Health and Education Act, already operates with comparatively light oversight; peptides could follow a similar trajectory, entering the market with structure-function claims rather than therapeutic ones, effectively sidestepping the need for premarket approval.
The FDA's historical role has been to act as a filter between laboratory science and consumer markets, ensuring that what reaches the public has met a minimum threshold of demonstrated safety. Weakening that filter for peptides would test whether market mechanisms — consumer reviews, third-party testing, brand reputation — can substitute for regulatory scrutiny. The track record of self-regulation in adjacent categories offers mixed evidence at best.
What remains unresolved is whether the political momentum behind deregulation will be matched by any institutional effort to generate the missing data. Without it, consumers gain access but not clarity — a trade-off whose consequences may take years to fully materialize. The question is whether the regulatory apparatus can evolve to accommodate faster access and robust evidence simultaneously, or whether the two will continue to be treated as competing priorities.
With reporting from Business of Fashion.
Source · Business of Fashion
